Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines

By Shitara Kohei  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 787-793

Springer Publishing Company

Access to resources Recommend Favorite

Phase II study of combination chemotherapy with irinotecan and cetuximab for pretreated metastatic colorectal cancer harboring wild-type KRAS

By Shitara Kohei   Yokota Tomoya   Takahari Daisuke   Shibata Takashi   Ura Takashi   Utsunomiya Setsuo   Inaba Yoshitaka   Yamaura Hidekazu   Sato Yozo   Najima Mina   Kawai Hiroki   Tajika Masahiro   Sawaki Akira   Yatabe Yasushi   Muro Kei  

Investigational New Drugs, Vol. 29, Iss. 4, 2011-08 ,pp. : 688-693

Springer Publishing Company

Access to resources Recommend Favorite

Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status

By Kang Myoung  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1607-1613

Springer Publishing Company

Access to resources Recommend Favorite

KRAS status predicts response to cetuximab in mCRC

By  

Inpharma, Vol. 1, Iss. 1641, 2008-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Wild-type KRAS state boosts response in colorectal cancer

By  

Inpharma, Vol. 1, Iss. 1647, 2008-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite